MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

volume building for mbp, page-16

  1. 5,270 Posts.
    lightbulb Created with Sketch. 244
    ...looks like this would be one of your competitors.

    Not really. It looks to me like this product is a treatment for nociceptive pain, not neuropathic pain like ACV1.

    Two different indications, two different markets.
 
watchlist Created with Sketch. Add MBP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.